Informação sobre produto
- (2R,3R,4S)-4-(1,3-Benzodioxol-5-yl)-1-[2-[(2,6-diethylphenyl)amino]-2-oxoethyl]-2-(4-propoxyphenyl)-3-pyrrolidinecarboxylic acid
- 3-Pyrrolidinecarboxylic acid, 4-(1,3-benzodioxol-5-yl)-1-[2-[(2,6-diethylphenyl)amino]-2-oxoethyl]-2-(4-propoxyphenyl)-, (2R,3R,4S)-
- 3-Pyrrolidinecarboxylic acid, 4-(1,3-benzodioxol-5-yl)-1-[2-[(2,6-diethylphenyl)amino]-2-oxoethyl]-2-(4-propoxyphenyl)-, [2R-(2α,3β,4α)]-
- 3-Pyrrolidinecarboxylicacid,4-(1,3-benzodioxol-5-yl)-1-[2-[(2,6-diethylphenyl)amino]-2-oxoethyl]-2-(4-propoxyphenyl)-,[2R-(2a,3b,4a)]-
- A 192621
- A 192621.1
A-192621 is a new drug that inhibits the activity of angiotensin II type 1 (AT1) receptors. This drug has been shown to significantly reduce systolic blood pressure in rats and to decrease cardiac hypertrophy in mice. A-192621 also reduces the glomerular filtration rate, which may be due to its ability to inhibit tubulointerstitial injury. The pharmacokinetic properties of this drug have been studied in detail and it has been shown that it can cross the blood-brain barrier and bind to basic fibroblast cells. A-192621 also shows an anti-diabetic effect by specifically inhibiting the production of natriuretic peptides.
Propriedades químicas
Consulta técnica sobre: 3D-VHA52954 A-192621
Se desejar solicitar um orçamento ou fazer uma encomenda, por favor, adicione os produtos ao seu carrinho e depois solicite um orçamento ou encomenda a partir do carrinho. É mais rápido, mais barato e poderá beneficiar-se dos descontos e outras vantagens disponíveis.
